ClinicalTrials.gg
CompletedNCT02187497Updated Jul 11, 2014

Pharmacokinetics of BIBR 277 in Hypertensive Patients

A Phase 2 interventional study of Low dose of BIBR 277 and Medium dose of BIBR 277 in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
60th of 74
93 · median 381
Started
1998
with 8 others
Phase 2
4 of 122
none open now
Registered
85th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 60th largest by enrollment of the 74 interventional ones that give a count, is one of 9 that started in 1998, is one of 4 in phase 2, and was the 85th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives was evaluated. The results of the present study are to be used in the Japanese population pharmacokinetics analysis

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: >=20 years
  • Sex: Either male or female
  • Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
  • BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.

Exclusion criteria

Exclusion Criteria:

  • Malignant hypertension
  • Renovascular hypertension
  • Severe heart failure ( functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
  • Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
  • Symptoms of cerebrovascular disorder
  • Serious hepatic dysfunction
  • Renal function disorder (serum creatinine >= 4.0 mg/dL)
  • Known to angiotensin II receptor antagonists
  • Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L))
  • Treatment with the other drug within 6 months of initiation of the present study
  • Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
  • Previous treatment with the trial medication of the present study
  • Otherwise judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Low dose of BIBR 277

    Drug: Low dose of BIBR 277

  • Experimental
    Medium dose of BIBR 277

    Drug: Medium dose of BIBR 277

  • Experimental
    High dose of BIBR 277

    Drug: High dose of BIBR 277

Interventions

  • DrugLow dose of BIBR 277
  • DrugMedium dose of BIBR 277
  • DrugHigh dose of BIBR 277
06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)

    Time frame: Pre-dose up to 24 hours after start of treatment

  2. Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)

    Time frame: Pre-dose up to 24 hours after start of treatment

  3. Maximum measured concentration of BIBR 277 in plasma (Cmax)

    Time frame: Pre-dose up to 24 hours after start of treatment

  4. Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)

    Time frame: Pre-dose up to 24 hours after start of treatment

  5. Terminal elimination half-time of BIBR 277 in plasma (t1/2)

    Time frame: Pre-dose up to 24 hours after start of treatment

Secondary outcomes

  1. Changes from baseline in blood pressure (systolic, diastolic, and mean)

    Time frame: Pre-dose up to 14 days after start of treatment

  2. Changes from baseline in pulse rate

    Time frame: Pre-dose up to 14 days after start of treatment

  3. Number of patients with adverse events

    Time frame: Up to 29 days

  4. Changes from baseline in laboratory test values

    Time frame: Pre-dose up to 14 days after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 1998 and a primary completion of Sep 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2014
First posted
Jul 11, 2014
Start
Jun 1998
Primary completionActual
Sep 1998
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02187497
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Jun 1998
Primary completion
Sep 1998
Last update
Jul 11, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion